---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-013948"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:59:19.609830+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio receives DSMB approval to continue Phase 3 Alzheimer's trial of buntanetap

## Summary
- DSMB issued positive recommendation on buntanetap safety at 6 months; trial continues without modification.
- Phase 3 AD trial is 40% complete; first symptomatic efficacy readout expected in early 2027.
- FDA indicated it may accept combined safety data from Alzheimer's and Parkinson's studies in future NDA submission.
- 6-month safety data in Alzheimer's patients consistent with those observed in Parkinson's patients.

## SEC filing metadata
- accession: 0001104659-26-013948
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465926013948/0001104659-26-013948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465926013948/tm266101d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-013948
- JSON: https://secwatch.observer/filing/0001104659-26-013948.json
- Plain text: https://secwatch.observer/filing/0001104659-26-013948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.